Eliem Therapeutics (NASDAQ:ELYM – Get Rating)‘s stock had its “neutral” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $6.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 73.91% from the company’s current price. HC Wainwright also issued estimates for Eliem Therapeutics’ FY2027 earnings at ($0.97) EPS.
Eliem Therapeutics Trading Down 5.2 %
Shares of Eliem Therapeutics stock opened at $3.45 on Wednesday. The company has a 50-day moving average of $3.54 and a two-hundred day moving average of $3.19. Eliem Therapeutics has a 12-month low of $2.21 and a 12-month high of $11.51. The stock has a market cap of $91.67 million, a PE ratio of -2.01 and a beta of 0.53.
Institutional Trading of Eliem Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the company. Silverarc Capital Management LLC boosted its holdings in shares of Eliem Therapeutics by 1.8% in the 4th quarter. Silverarc Capital Management LLC now owns 409,202 shares of the company’s stock valued at $1,502,000 after purchasing an additional 7,114 shares during the last quarter. Atom Investors LP boosted its holdings in shares of Eliem Therapeutics by 12.8% in the 4th quarter. Atom Investors LP now owns 75,651 shares of the company’s stock valued at $278,000 after purchasing an additional 8,577 shares during the last quarter. Driehaus Capital Management LLC lifted its holdings in shares of Eliem Therapeutics by 58.3% during the 4th quarter. Driehaus Capital Management LLC now owns 551,942 shares of the company’s stock valued at $2,026,000 after acquiring an additional 203,371 shares in the last quarter. BML Capital Management LLC acquired a new position in shares of Eliem Therapeutics during the 4th quarter valued at $6,698,000. Finally, Bank of Montreal Can acquired a new position in shares of Eliem Therapeutics during the 4th quarter valued at $93,000. 63.29% of the stock is owned by hedge funds and other institutional investors.
Eliem Therapeutics Company Profile
Eliem Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial.
- Get a free copy of the StockNews.com research report on Eliem Therapeutics (ELYM)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ’s Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.